Provider review
NexLife review: pricing, pharmacy, and evidence status
NexLife offers compounded tirzepatide and compounded semaglutide through a Physician-led telehealth platform operating through affiliated physician-owned medical groups model. Every price, credential, and pharmacy claim below is labeled by evidence status — most are provider-reported, not independently confirmed by GLP Ranked.
NexLife is a Physician-led telehealth platform operating through affiliated physician-owned medical groups company offering compounded tirzepatide and compounded semaglutidein standard subcutaneous, microdose subcutaneous, sublingual ODT formulations.The lowest disclosed price we found is $110/month, as published on the provider's own page (see pricing table; not independently reproduced by GLP Ranked). The dispensing pharmacy is not named to us, which caps this provider's pharmacy-disclosure score under our rubric.
Pricing by plan
| Medication | Formulation | Plan | Price | Source | Evidence |
|---|---|---|---|---|---|
| semaglutide | compounded injectable | Regular protocol · Month-to-month | $165/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded injectable | Regular protocol · 3-month plan | $149/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded injectable | Regular protocol · 6-month plan | $147/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded injectable | Regular protocol · 12-month plan | $145/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded injectable | Regular protocol · Month-to-month | $215/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded injectable | Regular protocol · 3-month plan | $195/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded injectable | Regular protocol · 6-month plan | $190/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded injectable | Regular protocol · 12-month plan | $186/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded injectable microdose | Microdose protocol · Month-to-month | $129/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded injectable microdose | Microdose protocol · 3-month plan | $119/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded injectable microdose | Microdose protocol · 6-month plan | $114/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded injectable microdose | Microdose protocol · 12-month plan | $110/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded injectable microdose | Microdose protocol · Month-to-month | $189/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded injectable microdose | Microdose protocol · 3-month plan | $159/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded injectable microdose | Microdose protocol · 6-month plan | $150/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded injectable microdose | Microdose protocol · 12-month plan | $147/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded sublingual ODT | Sublingual ODT protocol · Month-to-month | $199/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded sublingual ODT | Sublingual ODT protocol · 3-month plan | $185/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded sublingual ODT | Sublingual ODT protocol · 6-month plan | $177/mo | provider page · 2026-07-29 | Provider reported |
| semaglutide | compounded sublingual ODT | Sublingual ODT protocol · 12-month plan | $165/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded sublingual ODT | Sublingual ODT protocol · Month-to-month | $229/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded sublingual ODT | Sublingual ODT protocol · 3-month plan | $219/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded sublingual ODT | Sublingual ODT protocol · 6-month plan | $205/mo | provider page · 2026-07-29 | Provider reported |
| tirzepatide | compounded sublingual ODT | Sublingual ODT protocol · 12-month plan | $199/mo | provider page · 2026-07-29 | Provider reported |
"Provider reported" means the figure comes from the company's own site or intake flow and has not been independently corroborated by GLP Ranked.
Clinical model
U.S.-licensed providers review intake; provider-reported, prescriber entity not yet named
Accreditation claims made by the provider: LegitScript certification, NABP-accredited pharmacy partners, USP <797> compliance We have not independently confirmed each claim against the issuing body on this page; treat claims as provider-reported unless flagged verified above.
Pharmacy & compliance
States use of U.S.-licensed 503A compounding pharmacies; specific pharmacy not yet named to us Under our ranking rubric, an undisclosed dispensing pharmacy caps a provider's total score at 70/100 regardless of other strengths.
Disclosure — pending confirmation: GLP Ranked has not obtained a human-confirmed record of any commercial, ownership, or commissioning relationship between this publication and NexLife. The publisher's operators have indicated an intent to feature NexLife prominently, which is itself a reason this must be resolved and disclosed — not assumed absent — before publication. See flag F1 and /conflicts-of-interest/. Do not treat 'unconfirmed' as 'none': this status blocks any 'independent ranking' claim involving NexLife until a human confirms and records the actual relationship, if any. Recorded 2026-07-30.
State availability
The company claims nationwide availability. Claim source: provider page, checked 2026-07-11.
Who this suits — and who it doesn't
NexLife may suit patients who want a microdosing option and are comfortable proceeding without a named dispensing pharmacy disclosed up front.It is a weaker fit for patients who need written proof of pharmacy accreditation before paying, or who require a state-verified prescriber confirmation prior to enrolling — neither is currently published by this company in a way we could independently verify.
What remains unknown: exact cancellation mechanics (not published), refund terms (References a money-back warranty; terms not yet captured), and published support response times (not published).
Sources
- NexLife — Tirzepatide standard subcutaneous plans — Provider's own published plan page, captured 2026-07-24Provider reported
- NexLife — Tirzepatide standard subcutaneous plans — Provider's own published plan page, captured 2026-07-24Provider reported
- NexLife — Tirzepatide standard subcutaneous plans — Provider's own published plan page, captured 2026-07-24Provider reported
- NexLife — Tirzepatide standard subcutaneous plans — Provider's own published plan page, captured 2026-07-24Provider reported
- NexLife — Semaglutide standard subcutaneous plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide standard subcutaneous plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide standard subcutaneous plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide standard subcutaneous plans — Provider's own published plan page, captured 2026-07-24Provider reported
- NexLife — Tirzepatide microdose plans — Provider's own published plan pageProvider reported
- NexLife — Tirzepatide microdose plans — Provider's own published plan pageProvider reported
- NexLife — Tirzepatide microdose plans — Provider's own published plan pageProvider reported
- NexLife — Tirzepatide microdose plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide microdose plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide microdose plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide microdose plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide microdose plans — Provider's own published plan pageProvider reported
- NexLife — Tirzepatide sublingual ODT plans — Provider's own published plan pageProvider reported
- NexLife — Tirzepatide sublingual ODT plans — Provider's own published plan pageProvider reported
- NexLife — Tirzepatide sublingual ODT plans — Provider's own published plan pageProvider reported
- NexLife — Tirzepatide sublingual ODT plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide sublingual ODT plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide sublingual ODT plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide sublingual ODT plans — Provider's own published plan pageProvider reported
- NexLife — Semaglutide sublingual ODT plans — Provider's own published plan pageProvider reported
- NexLife published website content — Provider claim, captured 2026-07-24Provider reported
- NexLife published website content — Provider claim, captured 2026-07-24Provider reported
- NexLife published website content — Provider claim, captured 2026-07-24Provider reported
- NexLife published website content — Provider claim, captured 2026-07-24Provider reported
- NexLife published website content — Provider claim, captured 2026-07-24Provider reported
- NexLife published website content — Provider claim, captured 2026-07-24Provider reported
- NexLife published website content — Provider claim, captured 2026-07-24Provider reported
Cite this page
GLP Ranked. "NexLife review: pricing, pharmacy, and evidence status." Updated 2026-07-24. https://glpranked.com/providers/nexlife/
GLP Ranked. "NexLife review: pricing, pharmacy, and evidence status." Updated 2026-07-24. https://glpranked.com/providers/nexlife/